Cytoplasmic Localization of RXRα Determines Outcome in Breast Cancer.

The aim of this retrospective study was to assess the prognostic value of cytoplasmic versus nuclear RXRα expression in breast cancer (BC) tissue samples and to correlate the results with clinicopathological parameters. In 319 BC patients, the expression of RXRα was evaluated via immunohistochemistry. Prognosis-determining aspects were calculated through uni- and multivariate analyses. Correlation analysis revealed a trend association with nuclear RXRα expression regarding an improved overall survival (OS) ( = 0.078), whereas cytoplasmic RXRα expression was significantly correlated with a poor outcomes in terms of both OS ( = 0.038) and disease-free survival (DFS) ( = 0.037). Strengthening these results, cytoplasmic RXRα was found to be an independent marker for DFS ( = 0.023), when adjusted to clinicopathological parameters, whereas nuclear RXRα expression was positively associated with lower TNM-staging, i.e., pT ( = 0.01), pN ( = 0.029) and pM ( = 0.001). Additionally, cytoplasmic RXRα expression was positively associated with a higher histopathological tumor grading ( = 0.02). Cytoplasmic RXRα was also found to be a negative prognosticator for Her-2neu-negative and triple-negative patients. Altogether, these findings support the hypothesis that the subcellular localization of RXRα plays an important role in carcinogenesis and the prognosis of BC. The expression of cytoplasmic RXRα is correlated with a more aggressive course of the disease, whereas nuclear RXRα expression appears to be a protective factor. These data may help to identify high-risk BC subgroups in order to find possible specific options in targeted tumor therapy.